Tariq Ahmad1, Teresa Wang2, Emily C O'Brien2, Marc D Samsky3, John A Pura2, Yuliya Lokhnygina2, Joseph G Rogers1, Adrian F Hernandez1, Damian Craig4, Dawn E Bowles5, Carmelo A Milano5, Svati H Shah6, James L Januzzi7, G Michael Felker1, Chetan B Patel8. 1. Division of Cardiology, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 3. Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina. 4. Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina. 5. Division of Cardiac Surgery, Duke University Medical Center, Durham, North Carolina. 6. Division of Cardiology, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina. 7. Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. 8. Division of Cardiology, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. Electronic address: chetan.patel@duke.edu.
Abstract
OBJECTIVES: The purpose of this study was to examine changes in a broad panel of biomarkers following left ventricular assist device (LVAD) support in advanced heart failure (HF). BACKGROUND: LVAD therapy mechanically unloads the failing heart and may result in reversal of certain aspects of the end-stage HF phenotype. Changes in markers of myocardial stress, fibrosis, inflammation, fluid homeostasis, and renal injury in this setting are unknown. METHODS: Amino-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3, ST2, copeptin, growth differentiation factor (GDF)-15, C-reactive protein (CRP), and neutrophil gelatinase associated lipocalin (NGAL) levels were measured in frozen plasma collected from 37 individuals prior to continuous flow LVAD implantation and a median of 136 (interquartile range: 94 to 180) days after implantation. RESULTS: The median age of patients was 68 years old. LVAD therapy was associated with significant decreases in NT-proBNP (3,093 to 2,090 pg/ml; p = 0.02), ST2 (67.5 to 45.2 ng/ml, p <0.01), galectin-3 (24.7 to 22.0 ng/ml; p = 0.04), GDF-15 (3,232 to 2,613 ng/l;p <0.001), hs-CRP (22.4 to 11.9 mg/l; p = 0.01), and copeptin (103 to 94 pmol/l; p = 0.003) but not NGAL (132 to 135 ng/ml; p = 0.06). Despite improvement over time, absolute values of each biomarker remained extremely abnormal. Greater reductions in biomarkers were noted in individuals with >25% decrease in NT-proBNP concentrations but reached statistical significance only in the case of galectin-3 (p = 0.01). CONCLUSIONS: The biomarker profile in patients after LVAD placement improves but nonetheless remains significantly abnormal. Our results suggest the need for targeted therapeutic interventions to mitigate such abnormalities and potentially increase rates of myocardial recovery.
OBJECTIVES: The purpose of this study was to examine changes in a broad panel of biomarkers following left ventricular assist device (LVAD) support in advanced heart failure (HF). BACKGROUND:LVAD therapy mechanically unloads the failing heart and may result in reversal of certain aspects of the end-stage HF phenotype. Changes in markers of myocardial stress, fibrosis, inflammation, fluid homeostasis, and renal injury in this setting are unknown. METHODS: Amino-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3, ST2, copeptin, growth differentiation factor (GDF)-15, C-reactive protein (CRP), and neutrophil gelatinase associated lipocalin (NGAL) levels were measured in frozen plasma collected from 37 individuals prior to continuous flow LVAD implantation and a median of 136 (interquartile range: 94 to 180) days after implantation. RESULTS: The median age of patients was 68 years old. LVAD therapy was associated with significant decreases in NT-proBNP (3,093 to 2,090 pg/ml; p = 0.02), ST2 (67.5 to 45.2 ng/ml, p <0.01), galectin-3 (24.7 to 22.0 ng/ml; p = 0.04), GDF-15 (3,232 to 2,613 ng/l;p <0.001), hs-CRP (22.4 to 11.9 mg/l; p = 0.01), and copeptin (103 to 94 pmol/l; p = 0.003) but not NGAL (132 to 135 ng/ml; p = 0.06). Despite improvement over time, absolute values of each biomarker remained extremely abnormal. Greater reductions in biomarkers were noted in individuals with >25% decrease in NT-proBNP concentrations but reached statistical significance only in the case of galectin-3 (p = 0.01). CONCLUSIONS: The biomarker profile in patients after LVAD placement improves but nonetheless remains significantly abnormal. Our results suggest the need for targeted therapeutic interventions to mitigate such abnormalities and potentially increase rates of myocardial recovery.
Authors: Lauren K Truby; Lakshmi Sridharan; Raul J Flores; A Reshad Garan; Douglas Jennings; Melana Yuzefpolskaya; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Paolo C Colombo; Veli K Topkara Journal: ASAIO J Date: 2019 Mar/Apr Impact factor: 2.872
Authors: Prateeti Khazanie; Bradley G Hammill; Chetan B Patel; Michael S Kiernan; Lauren B Cooper; Suzanne V Arnold; Timothy J Fendler; John A Spertus; Lesley H Curtis; Adrian F Hernandez Journal: J Card Fail Date: 2016-02-15 Impact factor: 5.712
Authors: Marat Fudim; Jacob P Kelly; Aaron D Jones; Omar F AbouEzzeddine; Andrew P Ambrosy; Stephen J Greene; Yogesh N V Reddy; Kevin J Anstrom; Brooke Alhanti; Gregory D Lewis; Adrian F Hernandez; G Michael Felker Journal: Am Heart J Date: 2019-11-16 Impact factor: 4.749
Authors: Tariq Ahmad; Jacob P Kelly; Robert W McGarrah; Anne S Hellkamp; Mona Fiuzat; Jeffrey M Testani; Teresa S Wang; Amanda Verma; Marc D Samsky; Mark P Donahue; Olga R Ilkayeva; Dawn E Bowles; Chetan B Patel; Carmelo A Milano; Joseph G Rogers; G Michael Felker; Christopher M O'Connor; Svati H Shah; William E Kraus Journal: J Am Coll Cardiol Date: 2016-01-26 Impact factor: 24.094